DeepMatter, the AIM-listed company focusing on digitizing chemistry, is pleased to announce that it has agreed to acquire from global publisher Springer Nature the entire issued share capital of Infochem GmbH (the “Acquisition” or “Infochem”), a specialist in cheminformatics, for a total consideration of approximately €2.0 million to be satisfied as to €0.36 million in […]

Partnership merges Schrödinger’s advanced modeling capabilities with TB Alliance’s expertise in tuberculosis biology to accelerate the development of next-generation treatments NEW YORK – Dec. 11, 2018 – Schrödinger and TB Alliance today announced a three-year research collaboration to speed the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced computational platform for drug discovery. The […]

Collaboration brings together Schrödinger’s in silico discovery capabilities with SPARC’s novel insights into CNS pathways to speed drug development NEW YORK and MUMBAI, India – Schrödinger and Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced a research collaboration to accelerate the discovery of novel CNS therapeutics by leveraging Schrödinger’s […]

NEW YORK and LAS VEGAS Accenture (NYSE: ACN) has created an open partner ecosystem designed to help independent software vendors (ISVs) and life sciences companies team more effectively to accelerate drug discovery efforts and, ultimately, improve patient outcomes. The ecosystem is an integral part of the cloud-based informatics research platform that Accenture and Merck (known as MSD outside the United […]

NEW YORK – Nov. 15, 2018 – Schrödinger, a privately held company revolutionizing drug discovery and materials design through advanced molecular simulations, today announced the appointment of veteran pharmaceutical executive Joel Lebowitz as chief financial officer. Mr. Lebowitz, a longtime senior executive at Merck, brings to the company deep experience in finance and business development. “Joel […]

We are pleased to announce Schrödinger software release 2018-4, which is available for download now. This quarterly release includes usability improvements and performance enhancements across all of our software. Of special note, the superposition of molecules, proteins, nucleic acids, and membranes is now significantly easier and more powerful. Additionally, a new workflow involving Glide MCS constrained […]

Provides students with the opportunity to design new drug-like molecules targeting fibrotic diseases and malaria with cutting-edge drug discovery software   CAMBRIDGE and NOTTINGHAM, UK – Optibrium™, a developer of software for drug discovery, today announced it had entered into a collaboration with the University of Nottingham, a pioneering research institution and university. Optibrium’s StarDrop™ software […]

NEW YORK and SHANGHAI – Schrödinger, a privately-held company revolutionizing drug discovery through advanced computational methods and enterprise software solutions, and WuXi AppTec, a leading pharmaceutical and medical device R&D enabling platform company, announced today that they have formed Faxian Therapeutics. The new venture will leverage the precision molecular design platforms developed by Schrödinger and […]

Ghent, Belgium – Budapest, Hungary |  Semantic search company ONTOFORCE and cheminformatics and bioinformatics software solution provider ChemAxon; have set up a collaboration to make it easier to search for linked chemical data. ChemAxon’s web-based molecule drawing and editing tool Marvin JSwill be integrated in ONTOFORCE’s DISQOVER platform. As such, researchers and others will be able to take advantage of […]

Optibrium, Intellegens and Medicines Discovery Catapult awarded funding to apply machine learning in drug discovery Funding to support Artificial Intelligence (AI) in drug discovery takes a significant step forward today as Optibrium™, Intellegens, and Medicines Discovery Catapult secure a grant from Innovate UK to fund a £1 million project. The program will see Optibrium, which […]